- Home
- MYSE vs LPTX Comparison
MYSE vs LPTX Comparison
Compare MYSE & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSE
- LPTX
- Stock Information
- Founded
- MYSE 2014
- LPTX 2011
- Country
- MYSE United States
- LPTX United States
- Employees
- MYSE N/A
- LPTX N/A
- Industry
- MYSE Telecommunications Equipment
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYSE Telecommunications
- LPTX Health Care
- Exchange
- MYSE Nasdaq
- LPTX Nasdaq
- Market Cap
- MYSE 9.4M
- LPTX 11.1M
- IPO Year
- MYSE 2021
- LPTX N/A
- Fundamental
- Price
- MYSE $2.06
- LPTX $0.30
- Analyst Decision
- MYSE
- LPTX Hold
- Analyst Count
- MYSE 0
- LPTX 1
- Target Price
- MYSE N/A
- LPTX N/A
- AVG Volume (30 Days)
- MYSE 102.0K
- LPTX 2.1M
- Earning Date
- MYSE 08-14-2025
- LPTX 08-14-2025
- Dividend Yield
- MYSE N/A
- LPTX N/A
- EPS Growth
- MYSE N/A
- LPTX N/A
- EPS
- MYSE N/A
- LPTX N/A
- Revenue
- MYSE $315.00
- LPTX N/A
- Revenue This Year
- MYSE N/A
- LPTX N/A
- Revenue Next Year
- MYSE N/A
- LPTX N/A
- P/E Ratio
- MYSE N/A
- LPTX N/A
- Revenue Growth
- MYSE N/A
- LPTX N/A
- 52 Week Low
- MYSE $1.11
- LPTX $0.22
- 52 Week High
- MYSE $9.34
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MYSE N/A
- LPTX 47.39
- Support Level
- MYSE N/A
- LPTX $0.26
- Resistance Level
- MYSE N/A
- LPTX $0.31
- Average True Range (ATR)
- MYSE 0.00
- LPTX 0.04
- MACD
- MYSE 0.00
- LPTX -0.00
- Stochastic Oscillator
- MYSE 0.00
- LPTX 44.76
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.